Annals of Oncology Advance Access originally published online on November 28, 2007
Annals of Oncology 2008 19(4):752-762; doi:10.1093/annonc/mdm541
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
hematologic malignancies |
Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin’s lymphoma
1 Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig
2 Surgery for Hematology and Oncology, Saarbrücken
3 Department of Hematology and Oncology, University Hospital Göttingen, Göttingen
4 Saarland University Medical School, Hospital of Medicine I, Homburg/Saar, Germany
* Correspondence to: M. Ziepert, Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Härtelstrasse 16–18, D-04107 Leipzig, Germany. Tel: +49-341-9716120; Fax: +49-341-9716119; E-mail: marita.ziepert{at}imise.uni-leipzig.de
Background: Little is known on the heterogeneity of hematotoxicity in patients receiving multicycle chemotherapy.
Patients and methods: We analyzed data of 1399 patients with aggressive lymphoma from trials using CHOP (combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone)-like therapies. Multivariate modeling was carried out for leukocytopenia, thrombocytopenia and anemia and the models were validated by two large independent datasets from trials with/without usage of the CD20-antibody rituximab.
Results: On the basis of these models, we are able to predict the remarkable heterogeneity of hematotoxicity and propose to use risk groups. Regarding leukocytopenia, the low toxicity risk group experienced World Health Organization grade 4 in <10% of the cycles while the high toxicity risk group in almost all cycles. For thrombocytopenia, groups were detectable with almost no grade 3 or 4 toxicity and others where two out of three cycles were affected. In a separate set of models, the first cycle toxicity was the strongest predictor for later hematotoxicity. The risk for leukocytopenia was associated with infections, antibiotic use, hospitalization and treatment-related mortality, indicating the clinical usefulness of the models. For the first time, a Web-based tool is made available to easily predict the hematotoxicity in clinical practice (www.toxcalculator.com).
Conclusion: This analysis has implications for patient management and prophylaxis.
Key words: aggressive lymphoma, hematotoxicity, prognostic factors, prophylaxis
Received for publication June 1, 2007. Revision received October 11, 2007. Accepted for publication October 24, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Matsubara, M. Ono, A. Negishi, H. Ueno, T. Okusaka, J. Furuse, K. Furuta, E. Sugiyama, Y. Saito, N. Kaniwa, et al. Identification of a Predictive Biomarker for Hematologic Toxicities of Gemcitabine J. Clin. Oncol., May 1, 2009; 27(13): 2261 - 2268. [Abstract] [Full Text] [PDF]
|
|